A novel group of antidiabetic drugs that constitutes the sodium glucose transporter 2 (SGLT2) inhibitors have displayed encouraging results in patients with chronic heart failure (CHF) having diabetes mellitus Type-2 (T2DM). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.